News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Ariel Dora Stern: Four Decades of Orphan Drugs and Priorities for the Future
Photo taken from Ariel Dora Stern/LinkedIn
Jul 8, 2024, 06:36

Ariel Dora Stern: Four Decades of Orphan Drugs and Priorities for the Future

Ariel Dora Stern, Professor at Hasso Plattner Institute, shared on X:

“Published today in the NEJM: Four Decades of Orphan Drugs and Priorities for the Future with Michael Sinha and Arti Rai.”

Source: Ariel Dora Stern/X

Ariel Dora Stern Arti Rai cancer Michael Sinha NEJM OncoDaily Oncology
Special Coverage
Science
Jan 16, 2025, 14:16
Cecilia Pompili: Terrific paper from Dr Melinda L. Hsu on unmet needs and QoL in NSCLC survivors
Career
Jan 16, 2025, 14:12
St. Jude Global Critical Care team is looking for a Clinical Research Scientist
Career
Jan 16, 2025, 14:06
Antonio Gualberto: I’m starting a new position as Global Head, Due Diligence Oncology at EMD Serono
Blog
Jan 16, 2025, 13:56
Miriam Mutebi: Stories like Claire’s haunt us as clinicians
Blog
Jan 16, 2025, 13:39
NHS England starts sending bowel cancer screening tests to over-50s
Blog
Jan 16, 2025, 13:38
Justin Stebbing: Princess of Wales "in remission" from cancer
Career
Jan 16, 2025, 13:33
Daniel Mckenzie: Started my role at KidzCan Zimbabwe as an Executive Director
Science
Jan 16, 2025, 13:29
Chang-il Hwang: How organoid technology is transforming pancreatic cancer research
Blog
Jan 16, 2025, 13:22
Prisca Githuka: I rang the bell at the finish line after 10 years of being on Cancer hormonal treatment
Blog
Jan 16, 2025, 13:21
Akhil Santhosh: Prevention of dermatologically adverse events with amivantamab combinations
Radiotherapy
Jan 16, 2025, 13:14
What Is Palliative Radiotherapy and How It Works? Pros and Cons
Opinion
Jan 16, 2025, 13:08
Amol Akhade: OS difference in first line Cdk inhibitors plus AI, amongst Palbociclib, Ribociclib and abemaciclib in MBC